bms-963272
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02327273)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- 2-acylglycerol O-acyltransferase 2INHIBITOR
MOGAT2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C2=C(c3nn[nH]n3)C(O)=N[C@@](c3ccc(OCCCC(F)(F)F)cc3)(C(F)(F)F)C2)cc1- Mol. weight
- 525.45 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3912712 ↗
Also known as
- bms-963272
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04766476 | Phase 1 | Feb 24, 2021 | Bristol-Myers Squibb |
| NCT04124003 | Phase 1 | Oct 10, 2019 | Bristol-Myers Squibb |
| NCT04116632 | Phase 1 | Oct 5, 2019 | Bristol-Myers Squibb |
| NCT02327273 | Phase 1 | Oct 1, 2014 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 1 | 2014 |
1 organizations
Page 1 / 1